Treatment of polycythemia vera with imatinib mesylate

Leukemia Research

Volumn 36, Issue 2, 2012, Pages 156-162

  Silver, Richard T ^a   Bourla, Michael H ^b   Vandris, Katherine ^a   Fruchtman, Steven ^b   Spivak, Jerry L ^c   Feldman, Eric J ^a   Salvado, August J ^d  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Imatinib mesylate; Myeloproliferative disorder; Myeloproliferative neoplasm; Myelosuppresive therapy; Polycythemia vera; Tyrosine kinase inhibitor

Indexed keywords

ANAGRELIDE; HYDROXYUREA; IMATINIB; NARCOTIC ANALGESIC AGENT; RECOMBINANT ALPHA2B INTERFERON;

ADULT; AGED; ARTICLE; BLOATING; BONE MARROW APLASIA; BONE MARROW TOXICITY; BONE PAIN; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; EDEMA; ERYTHROPOIESIS; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN TISSUE; LEG CRAMP; LEG EDEMA; LIVER DYSFUNCTION; LOOSE FECES; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MUSCLE CRAMP; MYELOFIBROSIS; NAUSEA; OPEN STUDY; PERIORBITAL EDEMA; PHLEBOTOMY; POLYCYTHEMIA VERA; PRIORITY JOURNAL; SIDE EFFECT; SKIN TOXICITY; SPLEEN SIZE; THROMBOCYTOPENIA; THROMBOCYTOSIS; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; POLYCYTHEMIA; POLYCYTHEMIA VERA; PROGNOSIS; PYRIMIDINES; THROMBOCYTOSIS;

EID: 84855200309     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.09.001     Document Type: Article

References (40)

1. Spivak J.L. Narrative review: thrombocytosis, polycythemia vera, and JAK2 mutations: the phenotypic mimicry of chronic myeloproliferation. Ann Intern Med 2010, 152:300-306.
2. Silver R.T. Long-term effects of the treatment of polycythemia vera (PV) with recombinant interferon-alpha (rIFNα). Cancer 2006, 107:451-458.
3. Spivak J.L. Polycythemia vera: myths, mechanisms and management. Blood 2002, 100:4272-4290.
4. Berk P.D., Goldberg J.D., Donovan P.B., et al. Therapeutic recommendations in p polycythemia vera based on polycythemia vera study group protocols. Semin Hematol 1986, 23:132-143.
5. Kiladjian J.J., Cassinat B., Turlure P., et al. High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood 2006, 108:2037-2040.
6. Charache S. Who should get HU? And how?. Blood 2002, 99:1.
7. Bristol Myers Squibb Oncology Product Information Sheet 2001, 105(March):3327A2.
8. Ranta D., Bonmati C. Images in clinical medicine. Acquired melanonychia. New England Journal of Medicine 2009, 361:1188.
9. Najean Y., Dresch C., Rain J.D., et al. The very-long-term course of polycythaemia: a complement to the previously published data of the polycythaemia vera study group. Br J Haematol 1994, 86:233-235.
10. Najean Y., Rain J.D. Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood 1997, 90:3370-3377.
11. Kiladjian J.J., Chevret S., Dosquet C., et al. Long-term outcome in polycythemia vera (PV): final analysis of a randomized trial comparing hydroxyurea (HU) to pipobroman (PI). Blood 2008, 112:1746.
12. Hensley M.L., Peterson B., Silver R.T., et al. Risk factors for severe neuropsychiatric toxicity in patients receiving interferon alfa-2b and low-dose cytarabine for chronic myelogenous leukemia: analysis of cancer and leukemia group B 9013. J Clin Oncol 2000, 18:1301-1308.
13. Spivak J.L., Silver R.T. The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal. Blood 2008, 112:231-239.
14. Kiladjian J.J., Cassinat B., Chevret S., et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 2008, 112:3065-3072.
15. Gaikwad A., Verstovsek S., Yoon D., et al. Imatinib effect on growth and signal transduction in polycythemia vera. Exp Hematol 2007, 35:931-938.
16. Oehler L., Jaeger E., Eser A., et al. Imatinib mesylate inhibits autonomous erythropoiesis in patients with polycythemia vera in vitro. Blood 2003, 102:2240-2242.
17. Pardanani A., Tefferi A. Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders. Blood 2004, 104:1931-1939.
18. Zaleskas V.M., Krause D.S., Lazarides K., et al. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F. PLoS One 2006, 1:e18.
19. Fontalba A., Real P.J., Fernandez-Luna J.L., et al. Identification of c-Kit gene mutations in patients with polycythemia vera. Leuk Res 2006, 30:1325-1326.
20. Silver R.T. Imatinib mesylate (Gleevec™) reduces phlebotomy requirements in polycythemia vera. Leukemia 2003, 17:1186-1187.
21. Silver R.T. Treatment of polycythemia vera with recombinant interferon alpha (rIFNalpha) or imatinib mesylate. Curr Hematol Rep 2005, 4:235-237.
22. Jones A.V., Silver R.T., Waghorn K., et al. Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha. Blood 2006, 107:3339-3341.
23. Nussenzveig R.H., Cortes J., Sever M., et al. Imatinib mesylate therapy for polycythemia vera: final result of a phase II study initiated in 2001. Int J Hematol 2009, 90:58-63.
24. Jones C.M., Dickinson T.M., Salvado A. Phase II open label trial of imatinib in polycythemia rubra vera. Int J Hematol 2008, 88:489-494.
25. Hasselbalch H. Imatinib mesylate in polycythemia vera. A heterogeneous response pattern but a consistent reduction in phlebotomy requirements. Blood (ASH Annual Meeting Abstracts) 2004, 104. Abstract 4747.
26. Jones C.M., Dickinson T.M. Polycythemia vera responds to imatinib mesylate. Am J Med Sci 2003, 325(149):152.
27. Manoharan A., Horsley R., Pitney W.R. The reticulin content of bone marrow in acute leukaemia in adults. Br J Haematol 1979, 43:185-190.
28. Ellis J.T., Silver R.T., Coleman M., et al. The bone marrow in polycythemia vera. Semin Hematol 1975, 12:433-444.
29. Ellis J.T., Peterson P. The bone marrow in polycythemia vera. Pathol Annu 1979, 14:383-403.
30. Najfeld V., Conventional Molecular cytogenetics of Ph-negative chronic myeloproliferative disorders in myeloproliferative disorders: biology and management 2008, Informa Healthcare, New York, pp. 51-68.
31. Najfeld V., Tripodi J., Scalise A., et al. Jumping translocations of the long arms of chromosome 1 in myeloid malignancies is associated with high risk of transformation to acute leukemia. Br J Haematol 2010, 151:288-291.
32. Barosi G., Birgegard G., Finazzi G., et al. Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood 2009, 113:4829-4833.
33. Salie R., Silver R.T. Uncommon or delayed adverse events associated with imatinib treatment for chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk 2010, 10:331-335.
34. Marchioli R., Finazzi G., Landolfi R., et al. Vascular and neoplastic risk in large cohort of patients with polycythemia vera. J Clin Clin Oncol 2005, 23:2224-2232.
35. Silver R.T. Update on the treatment of polycythemia vera with recombinant interferon alfa or imatinib mesylate. Curr. Hematologic Malignancy Rep 2007, 2:43-46.
36. Ellis J.T., Peterson P., Galler S., Rappaport H. Studies of the bone marrow in polycythemia vera and the evolution of myelofibrosis in second hematologic malignancies. Semin Hematol 1986, 23:144-158.
37. Tefferi A., Thiele J., Orazi A., et al. Proposals and rationale for revision of World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007, 110:1092-1097.
38. Hasselbalch H.C., Bjerrum O.W., Jensen B.A., et al. Imatinib mesylate in idiopathic and postpolycythemic myelofibrosis. Am J Hematol 2003, 74:238-242.
39. Castagnetti F., Palandri F., Amabile M., et al. Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML working party. Blood 2009, 113:3428-3434.
40. Tefferi A., Vainchenker W., Myeloproliferative neoplasms: molecular pathophisiology Essential Clinical Understanding, and Treatment Strategies. J Clin Oncol 2011, 29:573-582.